Keros Therapeutics, INC Form 4 insider transactions

Keros Therapeutics, Inc. Director Carl L. Gordon was granted 5,250 Restricted Stock Units and 10,500 stock options, aligning his compensation with the company's long-term performance.

Keros Therapeutics, Inc. Director Nima Farzan was granted 5,250 Restricted Stock Units and options to purchase 10,500 shares of common stock, aligning executive interests with shareholder value.

Keros Therapeutics, Inc. Director and 10% owner Tomer Kariv has acquired 5,250 restricted stock units and 10,500 stock options, aligning his interests further with shareholders.

Ran Nussbaum, a Director and 10% Owner of Keros Therapeutics, Inc., reported the acquisition of 5,250 restricted stock units and 10,500 stock options on June 4, 2025.

Keros Therapeutics Director Jean Jacques Bienaime received a grant of 5,250 restricted stock units and options to purchase 10,500 shares of common stock on June 4, 2025.

ADAR1 Capital Management and related entities increase their holdings in Keros Therapeutics through a series of open market purchases and adjustments to cash-settled total return swaps.

Jasbir Seehra, CEO of Keros Therapeutics, exercised stock options and acquired shares of common stock, increasing their total holdings.

Keros Therapeutics' Chief Medical Officer, Yung H. Chyung, was granted 44,000 restricted stock units (RSUs) on February 18, 2025, which vest over a two-year period.

Keith Regnante, CFO of Keros Therapeutics, reports the acquisition of 44,000 shares of common stock through a restricted stock unit award.

Christopher Rovaldi, Chief Operating Officer of Keros Therapeutics, acquired 60,000 shares of common stock on February 18, 2025, through a restricted stock unit (RSU) award.

Keith Regnante, CFO of Keros Therapeutics, files an amendment to a Form 4, correcting the dates of transactions involving common stock.

Chief Medical Officer of Keros Therapeutics, Yung H. Chyung, reports the acquisition of 110,000 employee stock options.

Director Carl L. Gordon reported the sale of Keros Therapeutics (KROS) stock held indirectly through OrbiMed funds on August 13, 2024.

OrbiMed Advisors LLC, along with related entities, sold shares of Keros Therapeutics, Inc. on August 13, 2024.

Director Jean Jacques Bienaime of Keros Therapeutics, Inc. acquired 17,600 stock options on June 3, 2024, at a price of $48.67.

Director Alpna Seth acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024, at an exercise price of $46.31.

Director Tomer Kariv of Keros Therapeutics acquired 10,000 stock options at an exercise price of $46.31 on May 30, 2024.

Director Ran Nussbaum acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024.

Director Julius Knowles acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024.

Mary Ann Gray, a director of Keros Therapeutics, acquired 10,000 stock options on May 30, 2024, at an exercise price of $46.31.

Director Carl L. Gordon acquired 10,000 stock options in Keros Therapeutics, Inc. at an exercise price of $46.31 on May 30, 2024.

Director Nima Farzan acquired 10,000 stock options in Keros Therapeutics, Inc. on May 30, 2024, at an exercise price of $46.31.